Cempra (NASDAQ:CEMP) : Wednesdays money flow data in Cempra (NASDAQ:CEMP) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $0.76 million, whereas, $0.63 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.2, in favor of the bulls. The total money flow into the stock was $0.13 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $0.01 million. The total value of block trades done on upticks was $0.01 million. Cempra (NASDAQ:CEMP) fell $0.01 and traded at $16.27, down -0.06% for the day, over previous days close. On a weekly basis, the shares are -6.55% over the previous weeks close.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Chief Commercial Officer) of Cempra, Inc., Moore David, had purchased 500 shares in a transaction dated on March 1, 2016. The transaction was executed at $16.18 per share with total amount equaling $8,090. Currently the company Insiders own 17.8% of Cempra shares according to the proxy statements. Institutional Investors own 81.78% of Cempra shares. During last six month period, the net percent change held by insiders has seen a change of 50%.
The company shares have dropped -51.83% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $46.99 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $17.49 and the 200 Day Moving Average price is recorded at $19.07. Cempra (NASDAQ:CEMP): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $16.50 and $16.10 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $16.66. The buying momentum continued till the end and the stock did not give up its gains. It closed at $16.54, notching a gain of 1.60% for the day. The total traded volume was 615,657 . The stock had closed at $16.28 on the previous day.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.